{"entity":{"id":"nct07284758","kind":"trial","name":"A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma","aka":[],"tldr":"A phase 2 trial of Dexamethasone in multiple myeloma, run by C4 Therapeutics, Inc., now recruiting.","summary":"A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma is a phase 2 interventional study registered as NCT07284758 by C4 Therapeutics, Inc., with 100 participants planned, started 2026-02-18 and due to reach its primary completion in 2030-03. Interventions recorded: Cemsidomide, Dexamethasone. Conditions listed: Multiple Myeloma, Relapsed/Refractory Multiple Myeloma. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07284758","url":"https://clinicaltrials.gov/study/NCT07284758"}],"tags":["ctgov-ingest"],"related":[],"cancers":["multiple-myeloma","myeloma-relapsed-refractory"],"sections":[],"technologies":["antiemetic-therapy"],"targets":[],"drugs":["dexamethasone"],"companies":["c4-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07284758","phase":"2","setting":"A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma","sponsor":"C4 Therapeutics, Inc.","participation":[{"nct":"NCT07284758","source":"https://clinicaltrials.gov/study/NCT07284758","fetchedAt":"2026-10-07T16:55:38.126Z","studySha256":"d1c407cbcc6c1f12fd5deb6d6485a43bcfb77ed1a9135038f0a91776d13d3d81","overallStatus":"RECRUITING","lastUpdatePosted":"2026-08-06","leadSponsor":"C4 Therapeutics, Inc.","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":100,"enrolmentType":"ESTIMATED","siteCount":21,"recruitingSiteCount":21,"countries":["United Kingdom","United States"]}],"started":"2026-02-18","startedType":"actual","enrolled":100,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07284758/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"},{"id":"myeloma-relapsed-refractory","kind":"cancer","name":"Relapsed or refractory multiple myeloma","route":"/cancers/myeloma-relapsed-refractory/"}],"technology":[{"id":"antiemetic-therapy","kind":"technology","name":"Antiemetics for chemotherapy-induced nausea and vomiting","route":"/technologies/antiemetic-therapy/"}],"drug":[{"id":"dexamethasone","kind":"drug","name":"Dexamethasone","route":"/drugs/dexamethasone/"}],"company":[{"id":"c4-therapeutics","kind":"company","name":"C4 Therapeutics","route":"/companies/c4-therapeutics/"}]}}